Colinz Labs Reports Strong Financial Performance in Q2 of FY 2024-2025
Colinz Laboratories, a microcap pharmaceutical company, has announced its financial results for the quarter ending September 2024. Despite being given a 'Sell' call by MarketsMojo, the company has shown positive performance with the highest annual operating cash flow and quarterly profits in the last five quarters. The company's EPS and liquidity have also improved.
Colinz Laboratories, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Sell' call by MarketsMOJO.Despite this, Colinz Labs has shown positive financial performance in the second quarter of the fiscal year 2024-2025. In the last three months, the company's score has improved from 7 to 9.
According to the September 2024 financials, Colinz Labs has several factors working in its favor. The company has generated the highest annual operating cash flow of Rs 1.03 crore in the last three years, indicating strong cash revenues from business operations. Additionally, the company's quarterly operating profit (PBDIT) has been the highest at Rs 0.17 crore in the last five quarters, showing a positive trend in the near term. The same can be said for the company's quarterly profit before tax less other income (PBT) and profit after tax (PAT), which have both been the highest in the last five quarters.
Furthermore, Colinz Labs has also shown an increase in earnings per share (EPS) in the last five quarters, with the highest being Rs 0.63. This indicates that the company has been able to create higher earnings for its shareholders. In terms of liquidity, the company's cash and cash equivalents have been the highest at Rs 8.04 crore in the last six half-yearly periods, showing an improvement in short-term liquidity. Additionally, the company has been able to settle its debtors faster, with the debtors turnover ratio being the highest at 8.48 times in the last five half-yearly periods.
Overall, Colinz Laboratories has shown positive financial performance in the recent quarter, with several factors working in its favor. Investors should keep an eye on the company's future performance to make informed decisions.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
